This article has Open Peer Review reports available.
ZIC1 modulates cell-cycle distributions and cell migration through regulation of sonic hedgehog, PI3K and MAPK signaling pathways in gastric cancer
- Jing Zhong†1,
- Shujie Chen†2,
- Meng Xue2,
- Qin Du1,
- Jianting Cai1,
- Hongchuan Jin3,
- Jianmin Si2 and
- Liangjing Wang1Email author
© Zhong et al.; licensee BioMed Central Ltd. 2012
Received: 13 November 2011
Accepted: 16 July 2012
Published: 16 July 2012
ZIC1, a vital transcription factor with zinc finger domains, has been implicated in the process of neural development. We previously showed that ZIC1 may function as a tumour suppressor in gastrointestinal cancers. However, the molecular mechanism underlying ZIC1 participation in tumour progression remains unknown.
The role of ZIC1 on cell proliferation and migration was examined. The regulation of sonic hedgehog (Shh), phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling pathways after ectopic expression of ZIC1 in gastric cancer cells were evaluated.
Overexpression of ZIC1 contributes to the inhibition of cell proliferation migration and cell-cycle distribution in gastric cancer. The modulation of G1/S checkpoint by ZIC1 is mainly mediated through the regulation of cyclin-dependent kinases (p21 Waf1/Cip1, p27 Kip1 and cyclin D1). In addition, ZIC1 can inactivate the level of phospholated Akt and Erk1/2, and transcriptionally regulate sonic hedgehog (Shh) signaling, thus leading to regulate the expression of p21 Waf1/Cip1 and cyclin D1. Finally, we have systemically identified ZIC1 downstream targets by cDNA microarray analysis and revealed that 132 genes are down-regulated and 66 genes are up-regulated after transfection with ZIC1 in gastric cancer cells. These candidate genes play critical roles in cell proliferation, cell cycle and cell motility.
Overexpression of ZIC1 results in inactivation of Shh, PI3K and MAPK signaling pathways, as well as regulation of multiple downstream targets which are essential for the development and progression of gastric cancer. ZIC1 serves as a potential therapeutic target for gastric cancer.
ZIC1, one of five ZIC family genes, is involved in a variety of developmental processes, including neurogenesis and myogenesis [1, 2]. Recently, ZIC1 has been documented to participate in the progression of human tumours including medulloblastoma, endometrial cancers, mesenchymal neoplasms and liposarcoma cancers [3–6]. We have previously shown that ZIC1 gene is significantly downregulated in gastric cancer tissues and cell lines when compared with that of normal gastric tissues. In addition, ZIC1 potentially serves as a tumour suppressor by inhibiting cell proliferation in gastric and colorectal cancer cells [7, 8]. As an important transcription factor, ZIC1 is essential to the regulation of Hedgehog signaling (Hh), Bone morphogenetic protein (BMP), and Notch signaling pathways in neural development [2, 9]. However, little is known about how ZIC1 regulates signal pathways and their related downstream targets in cancer progression.
Gastric cancer is the second leading cause of cancer-related death worldwide [10, 11]. Hh signaling is one of the key oncogenic signaling pathways involved in gastric carcinogenesis [12, 13]. Sonic hedgehog (Shh), a member of the mammalian Hh family , has been demonstrated to be both upregulated in gastric cancer tissues by in situ hybridization assay and essential for the progression of gastric cancer [13, 15]. Hh signaling pathway is activated by Shh binding with the Patched (Ptch)- Smoothened (Smo) membrane-receptor complex . The activation of Shh promotes gastric cancer cell differentiation and proliferation. It has been reported that ZIC1 could reduce the expression of PTCH1 and Shh genes in neural tissue during forebrain development . In contrast, evidence has shown that the Shh represses the expression of ZIC1 during neural tube development . Nevertheless, the influence of ZIC1 on the Hh signaling pathway in gastric cancer remains unknown.
ZIC1 also regulates numerous targets including cyclin D1, p27, Wnt1 and Wnt7a during neural development in xenopus ectodermal explants and mutant mice models [9, 19, 20]. We are particularly interested in cell-cycle regulators important for cancer cell proliferation and differentiation. We have previously shown that overexpression of ZIC1 can alter G1/S transition in gastric cancer cells . Several mechanisms of Cyclin dependent kinases (CDKs) are involved in the regulation of G1/S checkpoint in human cancers . During transition from G1 to S phase, cyclin D which forms active complexes with CDK4 is up-regulated in gastric cancer [22, 23]. Loss of cyclin dependent kinase inhibitors such as p21Waf1/Cip1 and p27Kip 1 promote CDK2 activity and regulate the G1/S transition [12, 24]. Recent studies have demonstrated that mutant ZIC1 or force overexpression of ZIC1 regulates the expression of p27 Kip 1 in mice cerebellar tissues and liposarcoma cells [3, 20]. Interestingly, the Shh signaling pathway negatively regulates p21 Waf1/Cip1 and cyclin D1 in a GLI1-dependent manner [16, 25]. However, whether ZIC1 can interplay with Shh pathway in the regulation of cell cycle distributions has not been defined. Elucidation of this signaling network may provide further insight into the role of ZIC1 in gastric cancer.
In our present study, we demonstrate that overexpression of ZIC1 suppresses gastric cancer cell migration and invasion, as well as alters the cell-cycle distributions. ZIC1 can transcriptionally downregulate the Shh signaling and suppress the level of phospholated Akt and Erk, thus leads to the regulation of cell-cycle regulator kinases p21Waf1/Cip1, p27Kip1 and cyclin D1 in gastric cancer cells. We also identified multiple important ZIC1 downstream targets in gastric cancer cells by cDNA microarray analysis.
ZIC1 inhibits proliferation, migration and invasion of gastric cancer cells
In addition, we determined the role of ZIC1 in cell migration and invasion in gastric cancer. Cell migration and invasion assays were performed in transwell migration and Matrigel-coated invasion assay systems, respectively. We observed that re-expression of ZIC1 significantly suppressed cell migration in AGS, BGC823 and SGC7901 gastric cancer cell lines (p < 0.001) (Figure 1C,D). In addition, re-expression of ZIC1 displayed a significantly lower activity of cellular invasion when compared to those empty vector transfectants in AGS cells (p < 0.05) (Additional file 1: Figure S1). These data suggest that ectopic expression of ZIC1 suppresses gastric cancer cell migration and invasion.
ZIC1 alters cell-cycle distributions and regulates the expression of cyclin-dependent kinases in gastric cancer cells
MAPK and PI3K pathways play vital roles in the regulation of cell-cycle kinases. We evaluated the expression of main downstream effectors of these two pathways, Erk1/2 and Akt, after stably introducing pCDNA3.1-ZIC1 to AGS, MKN28, BGC823 and SGC7901 gastric cancer cells (Figure 1A). We found that the phosphorylation levels of Erk1/2 and Akt were dramatically suppressed by overexpression of ZIC1 in all above cell lines tested (Figure 2C). These results suggested that the regulation of cell-cylce distribution by ZIC1 may be mediated through PI3K and MAPK pathways and their downstream cyclin-dependent kinases p21, p27 and cyclin D1 in gastric cancer.
ZIC1 suppresses the expression of Sonic hedgehog (Shh) in gastric cancer cells
Hedgehog (Hh) signaling pathway is involved in the ZIC1 regulation of cell-cycle and cell migration in gastric cancer cells
We also evaluated the effects of Shh signaling on gastric cancer cell migration. As shown in Figure 4 C and D, AGS, BGC823 and SGC7901 gastric cancer cell lines showed significant decrease in cellular migration after administration with cyclopamine (10 μM) for 24 h (p < 0.01). Collectively, these results demonstrate that ZICI may modulate the cell-cycle regulators and cell migration through Shh signaling in gastric cancer cells.
Gene expression profile changes by ectopic expression of ZIC1
Growing evidence has shown that ZIC1 is involved in the progression of several tumours [3–8]. It appears that ZIC1 is aberrantly expressed in certain types of cancer and differentially functions as a tumour suppressor or oncogenic gene. For instance, ZIC1 expression was reported to be low or absent in gastrointestinal and lung cancer cell lines, and was found to suppress gastrointestinal cancer cell proliferation [7, 8, 29]. In contrast, overexpression of ZIC1 in liposarcoma was found to promote cell proliferation and invasion . We and others have demonstrated that the epigenetic modulations including DNA methylation and histone remodeling, and genetic mutations may contribute to its differential expression patterns in cancers [3, 4, 7, 8]. It is becoming clear that as a zinc finger transcription factor, ZIC1 may modulate multiple downstream genes in neural tissue, colorectal cancer and liposarcoma cells [2, 3, 7, 9]. However, little is known about the mechanism underlying ZIC1 function in the development and progression of gastric cancer. Underscoring the key pathways and downstream targets regulated by ZIC1 may facilitate our understanding of its roles in tumorigenesis. Here, we have demonstrated that overexpression of ZIC1 results in significant inhibition of cell survival and impairment of cell migration. ZIC1 suppresses the Shh , PI3K and MAPK signaling pathways which are critical for the regulation of cell-cycle distributions and cell migration in gastric cancer. Moreover, ZIC1 inhibits cell cycle regulatory kinases, p21, p27 and cyclin D1, thus leading to G1/S cell cycle transit in gastric cancer cells. ZIC1 suppresses the Shh signaling pathway which is critical for the regulation of cell-cycle distributions and cell migration in gastric cancer.
MAPK and PI3K pathways play critical roles in cell proliferation, differentiation, and progression in a variety of human cancers . Recently, it was also reported that the activation of both pathways are essential to induce cell cycle entry [30, 31]. During this process, cyclin dependent kinase inhibitors p21, p27 and cyclin D/E participate in the regulation of p53 induced cell-cycle arrest [24, 32]. The activation of MAPK and its downstream kinase-Erk could not only lead to the induction of cyclin D1 and pass through G1/S checkpoint, but also the accumulation of p21 that inhibits cyclin E/CDK2 complexes to block S-phase entry . PI3K/Akt pathway could inactivate the Gsk3-β and FOXO transcription factors, thus inhibit cyclin D1 while induce p27 and p21 in the regulation of cell-cycle entry . We have shown that re-expression of ZIC1 effectively inactivate the phosphorylated Akt and Erk1/2 in AGS, MKN28, BGC823 and SGC7901 gastric cancer cell lines. In this regard, the CDK1 inhibitor p21 was activated, while cyclin D1 inactivated, after overexpression of ZIC1 in gastric cancer cells. Though the results need to be validated in future studies, our miroarray data have revealed that other key components of cell cycle kinase regulators including TP53INPI and CDKN2B, are deregulated with forced expression of ZIC1 in an individual MKN28 gastric cancer cell line (Figure 5 A and B). Therefore, we propose that ZIC1 regulates G1/S transit mainly through PI3K and MAPK pathways and downstream cell-cycle regulator kinases in gastric cancer cells.
Another major finding in our present study is that ZIC1 transcriptionally regulates Sonic hedgehog (Shh) signaling in gastric cancer cells. Aside from its central role on regulating gastric gland morphogenesis in human stomach, Shh signaling is also involved in the pathogenesis of gastric cancer [16, 33]. Shh is frequently activated in advanced gastric adenocarcinomas and associated with aggressive tumour behavior [13, 15, 33]. Previous studies have shown that Shh signaling promotes the motility and invasiveness of gastric cancer cells through TGF-β-ALK5-Smad3 pathway . Shh signaling could also regulate the expression of p21 and cyclin D1 in a Gli-dependent pathway [16, 25]. We have observed that inhibition of Shh signaling by administration with cyclopamine suppresses AGS, BGC823 and SGC7901 gastric cancer cell migration, and regulates the expression of p21 and cyclin D1 (Figure 4). These results are consistent with previously reported studies [25, 34]. Thus, we have revealed that ZIC1 plays important roles in gastric cancer progression by regulation of the Shh signaling pathway.
ZIC1 may regulate target genes in both sequence-specific and independent manners . ZIC1 could regulate the transcriptional expression of targets including cyclin D1, p27, Wnt1 and Wnt7a, and modulate Notch and BMP pathways in neural development [2, 9]. ZIC1 could counteract GLI by binding to GC-rich sequences, and suppress the expression of GLI-binding sequence directed reporter genes [9, 35]. We identified several ZIC potential target genes in gastric cancer cells by microarray analysis. These targets are closely related to cell cycle, cell proliferation and migration (Figure 5B). The association between ZIC and downstream targets might be a clue for understanding the potential perspective of ZIC proteins in the progression of gastric cancer.
Summarily, we propose a model that represents the pathways through which ZIC1 contributes to gastric cancer progression (Figure 5C). Overexpression of ZIC1 results in suppressing Hedgehog (Hh) signaling and its downstream targets including p21, p27 and cyclin D1. As a zinc finger transcription factor, ZIC1 also potentially modulates the transcriptional expression of target genes by directly binding to GC-rich sequences , thus functioning as a tumour suppressor by inhibition of cell proliferation, cell migration and invasion in gastric cancer.
Cell culture and treatment
The human gastric cancer cell lines (AGS, MKN28, BGC823 and SGC7901) were obtained from Riken Gene Bank (Japan) and American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were cultured in RPMI 1640 medium (Invitrogen, CA, USA) supplemented with 10 % fetal bovine serum (FBS) and incubated at 5% CO2, 37°C and 95 % humidity. Gastric cancer cell lines (AGS, BGC823, and SGC7901) were treated with 10 μM of cyclopamine (Sigma, St Louis, MO, USA) in DMSO for 24 hours. An equivalent concentration of the vehicle (DMSO) was used as the control.
AGS, MKN28, BGC823 and SGC7901 cells were cultured for 24 h in a 6-well plate and transfected with pCDNA 3.1-ZIC1 or pCDNA 3.1 empty vector using Fugene HD (Roche) according to the manufacturer's instructions. After 48 h, the transfectants were continuously selected in RPMI 1640 medium containing G418 (200–400 μg/mL) (Merck, Germany) for 14 days.
RT-PCR and quantitative real time PCR analysis
Total RNA (1 μg) was extracted using Trizol reagent (Invitrogen) following manufacturer’s instructions and reverse transcribed into cDNA with M-MLV RTase cDNA Synthesis Kit (Takara, Japan). The transcript levels of ZIC1 and Shh were determined by conventional RT-PCR with TaKaRa Taq polymerase (Takara, Japan) or Quantitative real-time PCR (qRT-PCR) with the SYBR Green Master Mix Kit (Takara, Japan) in an ABI 7500 PCR system. Primers used for ZIC1 were F: 5’-AAACTGGTTAACCACATCCGC and R: 5’-CTCAAACTCGCACTTGAAGG. Shh were F: 5’-GTAAGGACAAGTTGAACGCTTTG and R: 5’-GATATGTGCCTTGGACTCGTAGTA. Glyceraldehyde-3-;phosohate dehydrogenase (GAPDH) was used as an internal control. The transcript levels are expressed as 2-ΔΔCt values and relative expression fold change is normalized to GAPDH.
Cell viability assay
Cell viability was detected with a nonradioactive cell proliferation assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium (MTS) reagents (Promega, Madison, USA). Stable transfected cells were plated in 96-well (2000 cells/well) for 6 h, 24 h, 72 h and 120 h. The absorbance was measured at 490 nm after 1 h incubation with CellTiter 96 Aqueous One Solution reagent.
Cell-cycle and cell apoptosis analysis
Cell cycle distributions were detected by the flow cytometry analysis. Cells transfected with pCDNA3.1-ZIC1 or pCDNA3.1 empty vector were harvested and washed with PBS. Cellular DNA was stained with cell cycle staining solution containing propidium iodide (PI) at 4 °C in dark. Cell cycle was determined using a FACS Calibur and analyzed with the ModFitLT software (Phoenix, USA).
Cell apoptosis was performed using FITC Annexin V Apoptosis Detection Kit II (BD Pharmingen) by flow cytometry analysis. Transiently transfected cells were suspended in Annexin V Binding Buffer. Then FITC Annexin V and PI solutions were added in sequence. After incubation for 15 min, the stained cells were analyzed by flow FACScan flow cytometry (Becton Dickinson, USA).
Cell migration and invasion assays
Cell migration was assessed by modified Boyden transwell chambers assay (Coring, USA). Briefly, cells were cultured in serum-free medium for 24 h and 5 × 104 cells were plated to the upper chamber in 300 μL medium containing 5 % FBS. After 16 h of incubation, non-migratory cells in the upper chamber were carefully removed with a cotton swab. Migrated Cells were stained with DAPI Staining Solution. The cell numbers were randomly counted in five fields (×400 magnification).
Cell invasion was performed in a millipore 24-well coated with BD Matrigel. After starvation in serum-free medium for 24 h, 1 × 105 cells were plated to the upper chamber in 300 μL of medium containing 5 % FBS, while the lower chamber was filled with 600 μL of culture medium with 15 % FBS. After having been incubated for 30 h, the membranes were incubated with Cell Stain Solution (Millorpore, USA). The dye mixture was washed by Extraction Buffer and transferred to a 96-well for colorimetric measurement at 560 nm.
Western blot analysis
Total proteins were extracted from cells using radio-immunoprecipitation assay lysis buffer supplemented with protease inhibitor. Lysates were resolved on 6-12 % SDS-PAGE minigels and transferred to PVDF membranes (Millipore, Bedford, MA). Membranes were blocked in 5 % milk with TBST and incubated in 4°C overnight with following antibodies: ZIC1 (1:500; Abcam), phospho-Akt (1:1000; Cell Signaling), Akt (1:500; Abcam), phospho-Erk1/2 (1:1000; Cell Signaling), Erk1/2 (1:1000; Cell Signaling), p21Waf1/Cip1 (1:1000; Cell Signaling), p27 Kip1 (1:500; Epitomics), cyclin D1 (1:1000; Cell Signaling) and Shh (1:1000; Cell Signaling). Accordingly, secondary antibodies coupled to horseradish peroxidise (HRP) were visualized using a chemiluminescence with Las-4000 Imaging System (Fujifilm, Japan). The relative densities of proteins were quantified with Image J. software and normalized to β-actin (1:2500, Multisciences Biotech).
cDNA microarray analysis
Total RNA was isolated from MKN28 cells which stably transfected with pCDNA3.1-ZIC1 or pCDNA3.1 empty vector, and was reverse transcribed to cDNA. Labeled samples were hybridized with Agilent whole human genome containing more than 41,000 probes (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38924). The microarray data were analyzed using Agilent Feature Extraction software. We selected a fold change ≥1.5 or ≤ −1.5 as a significant difference.
Student’s t test was performed to compare two-independent data, while Chi-square or fisher exact test was used to analyze categorical variables. A cut-off of p < 0.05 was applied for statistical significance.
The project was supported by National Natural Science Foundation of China (30900676, 81071961), National Basic Research Program of China (973 Program) (2012CB945004) and Science and Technology Key project of Zhejiang Province in China (2009 C03012-3). The authors are grateful to Prof. Tianhua Zhou and Prof. Lei Guo for helpful suggestions and discussion; and Thomas R. Austin for critical review and editing of the manuscript.
- Aruga J, Yokota N, Hashimoto M, Furuichi T, Fukuda M, Mikoshiba K: A novel zinc finger protein, zic, is involved in neurogenesis, especially in the cell lineage of cerebellar granule cells. J Neurochem. 1994, 63 (5): 1880-1890.View ArticlePubMedGoogle Scholar
- Merzdorf CS: Emerging roles for zic genes in early development. Dev Dyn. 2007, 236 (4): 922-940. 10.1002/dvdy.21098.View ArticlePubMedGoogle Scholar
- Brill E, Gobble R, Angeles C, Lagos-Quintana M, Crago A, Laxa B, Decarolis P, Zhang L, Antonescu C, Socci ND, et al: ZIC1 overexpression is oncogenic in liposarcoma. Cancer Res. 2010, 70 (17): 6891-6901. 10.1158/0008-5472.CAN-10-0745.View ArticlePubMedPubMed CentralGoogle Scholar
- Pourebrahim R, Van Dam K, Bauters M, De Wever I, Sciot R, Cassiman JJ, Tejpar S: ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations. Febs Lett. 2007, 581 (26): 5122-5126. 10.1016/j.febslet.2007.09.061.View ArticlePubMedGoogle Scholar
- Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, et al: Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene. 2007, 26 (13): 1971-1982. 10.1038/sj.onc.1209986.View ArticlePubMedGoogle Scholar
- Yokota N, Aruga J, Takai S, Yamada K, Hamazaki M, Iwase T, Sugimura H, Mikoshiba K: Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res. 1996, 56 (2): 377-383.PubMedGoogle Scholar
- Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, Zhang J, Zhou T, Yu J, Si J, et al: ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One. 2011, 6 (2): e16916-10.1371/journal.pone.0016916.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang LJ, Jin HC, Wang X, Lam EK, Zhang JB, Liu X, Chan FK, Si JM, Sung JJ: ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun. 2009, 379 (4): 959-963. 10.1016/j.bbrc.2008.12.180.View ArticlePubMedGoogle Scholar
- Aruga J: The role of Zic genes in neural development. Mol Cell Neurosci. 2004, 26 (2): 205-221. 10.1016/j.mcn.2004.01.004.View ArticlePubMedGoogle Scholar
- Danaei G, Vander HS, Lopez AD, Murray CJ, Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005, 366 (9499): 1784-1793. 10.1016/S0140-6736(05)67725-2.View ArticlePubMedGoogle Scholar
- Hohenberger P, Gretschel S: Gastric cancer. Lancet. 2003, 362 (9380): 305-315. 10.1016/S0140-6736(03)13975-X.View ArticlePubMedGoogle Scholar
- Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ: Dysregulation of cellular signaling in gastric cancer. Cancer Lett. 2010, 295 (2): 144-153. 10.1016/j.canlet.2010.04.025.View ArticlePubMedGoogle Scholar
- Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis. 2005, 26 (10): 1698-1705. 10.1093/carcin/bgi130.View ArticlePubMedGoogle Scholar
- Echelard Y, Epstein DJ, St-Jacques B, Shen L, Mohler J, McMahon JA, McMahon AP: Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993, 75 (7): 1417-1430. 10.1016/0092-8674(93)90627-3.View ArticlePubMedGoogle Scholar
- Katoh Y, Katoh M: Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther. 2005, 4 (10): 1050-1054. 10.4161/cbt.4.10.2184.View ArticlePubMedGoogle Scholar
- Saqui-Salces M, Merchant JL: Hedgehog signaling and gastrointestinal cancer. Biochim Biophys Acta. 2010, 1803 (7): 786-795. 10.1016/j.bbamcr.2010.03.008.View ArticlePubMedGoogle Scholar
- Maurus D, Harris WA: Zic-associated holoprosencephaly: zebrafish Zic1 controls midline formation and forebrain patterning by regulating Nodal, Hedgehog, and retinoic acid signaling. Genes Dev. 2009, 23 (12): 1461-1473. 10.1101/gad.517009.View ArticlePubMedPubMed CentralGoogle Scholar
- Aruga J, Tohmonda T, Homma S, Mikoshiba K: Zic1 promotes the expansion of dorsal neural progenitors in spinal cord by inhibiting neuronal differentiation. Dev Biol. 2002, 244 (2): 329-341. 10.1006/dbio.2002.0598.View ArticlePubMedGoogle Scholar
- Merzdorf CS, Sive HL: The zic1 gene is an activator of Wnt signaling. Int J Dev Biol. 2006, 50 (7): 611-617. 10.1387/ijdb.052110cm.View ArticlePubMedGoogle Scholar
- Aruga J, Inoue T, Hoshino J, Mikoshiba K: Zic2 controls cerebellar development in cooperation with Zic1. J Neurosci. 2002, 22 (1): 218-225.PubMedGoogle Scholar
- Sharma PS, Sharma R, Tyagi R: Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr Cancer Drug Targets. 2008, 8 (1): 53-75. 10.2174/156800908783497131.View ArticlePubMedGoogle Scholar
- Arici DS, Tuncer E, Ozer H, Simek G, Koyuncu A: Expression of retinoblastoma and cyclin D1 in gastric carcinoma. Neoplasma. 2009, 56 (1): 63-67. 10.4149/neo_2009_01_63.View ArticlePubMedGoogle Scholar
- Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007, 6: 24-View ArticlePubMedPubMed CentralGoogle Scholar
- Abbas T, Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009, 9 (6): 400-414. 10.1038/nrc2657.View ArticlePubMedPubMed CentralGoogle Scholar
- Ohta M, Tateishi K, Kanai F, Watabe H, Kondo S, Guleng B, Tanaka Y, Asaoka Y, Jazag A, Imamura J, et al: p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res. 2005, 65 (23): 10822-10829. 10.1158/0008-5472.CAN-05-0777.View ArticlePubMedGoogle Scholar
- Park JM, Xian XS, Choi MG, Park H, Cho YK, Lee IS, Kim SW, Chung IS: Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. J Cell Biochem. 2011, 112 (4): 1192-1205. 10.1002/jcb.23041.View ArticlePubMedGoogle Scholar
- Xie K, Abbruzzese JL: Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. Cancer Cell. 2003, 4 (4): 245-247. 10.1016/S1535-6108(03)00246-0.View ArticlePubMedGoogle Scholar
- Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000, 406 (6799): 1005-1009. 10.1038/35023008.View ArticlePubMedGoogle Scholar
- Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau J, Graus F: ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol. 2008, 201–202: 163-165.View ArticlePubMedPubMed CentralGoogle Scholar
- Chambard JC, Lefloch R, Pouyssegur J, Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007, 1773 (8): 1299-1310. 10.1016/j.bbamcr.2006.11.010.View ArticlePubMedGoogle Scholar
- Arcaro A, Guerreiro AS: The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics. 2007, 8 (5): 271-306. 10.2174/138920207782446160.View ArticlePubMedPubMed CentralGoogle Scholar
- de Carcer G, Perez DCI, Malumbres M: Targeting cell cycle kinases for cancer therapy. Curr Med Chem. 2007, 14 (9): 969-985. 10.2174/092986707780362925.View ArticlePubMedGoogle Scholar
- van den Brink GR, Hardwick JC, Tytgat GN, Brink MA, Ten KF, Van Deventer SJ, Peppelenbosch MP: Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology. 2001, 121 (2): 317-328. 10.1053/gast.2001.26261.View ArticlePubMedGoogle Scholar
- Yoo YA, Kang MH, Kim JS, Oh SC: Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis. 2008, 29 (3): 480-490.View ArticlePubMedGoogle Scholar
- Koyabu Y, Nakata K, Mizugishi K, Aruga J, Mikoshiba K: Physical and functional interactions between Zic and Gli proteins. J Biol Chem. 2001, 276 (10): 6889-6892. 10.1074/jbc.C000773200.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/290/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.